A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis (XPORT-MF-034)

被引：2
|
作者：
Maher, Keri [1 ]
Rampal, Raajit K. [2 ]
Bose, Prithviraj [3 ]
Podoltsev, Nikolai A. [4 ]
Harrison, Claire N. [5 ]
Hong, Junshik [6 ]
Wang, Xulong [7 ]
Chamoun, Kamal [7 ]
Mascarenhas, John [8 ]
机构：
[1] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Yale Sch Med, Dept Hematol, Med, New Haven, CT USA
[5] Guys & St Thomas NHS Fdn Trust, London, England
[6] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea
[7] Karyopharm Therapeut, Newton, MA USA
[8] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Dept Med, New York, NY USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180695
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
634
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
    Yacoub, Abdulraheem
    Borate, Uma
    Rampal, Raajit
    Ali, Haris
    Wang, Eunice S.
    Gerds, Aaron T.
    Hobbs, Gabriela
    Kremyanskaya, Marina
    Winton, Elliott
    O'Connell, Casey
    Goel, Swati
    Oh, Stephen
    Schiller, Gary J.
    Assad, Albert
    Erickson-Viitanen, Sue
    Zhou, Feng
    Daver, Naval
    BLOOD, 2021, 138
  • [22] Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF
    Mesa, Ruben A.
    Gotlib, Jason
    Gupta, Vikas
    DiPersio, John F.
    Catalano, John
    Deininger, Michael W.
    Shields, Alan
    Miller, Carole B.
    Silver, Richard T.
    Talpaz, Moshe
    Winton, Elliott F.
    Harvey, Jimmie H., Jr.
    Hare, Thomas
    Erickson-Viitanen, Sue
    Sun, William
    Sandor, Victor A.
    Levy, Richard S.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2011, 118 (21) : 1642 - 1643
  • [23] MANIFEST-2, a global, phase 3, randomized, double-blind, active-control study of CPI-0610 and Ruxolitinib vs. placebo and Ruxolitinib in JAKi-treatment-naive Myelofibrosis (MF) patients
    Al-Ali, H. K.
    Mascarenhas, J.
    Harrison, C.
    Luptakova, K.
    Wang, J.
    Colak, G.
    Shao, J.
    Bobba, S.
    Trojer, P.
    Humphrey, J.
    Verstovsek, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 164 - 164
  • [24] A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Evaluating Navitoclax in Combination with Ruxolitinib in Patients with Myelofibrosis (TRANSFORM-1)
    Potluri, Jalaja
    Harb, Jason
    Masud, Abdullah A.
    Hutti, Jessica E.
    BLOOD, 2020, 136
  • [25] Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)
    Pardanani, Animesh
    Harrison, Claire N.
    Cortes, Jorge E.
    Cervantes, Francisco
    Mesa, Ruben A.
    Milligan, Donald
    Masszi, Tamas
    Mishchenko, Elena
    Jourdan, Eric
    Vannucchi, Alessandro M.
    Drummond, Mark
    Jurgutis, Mindaugas
    Kuliczkowski, Kazimierz
    Gheorghita, Emanuil
    Passamonti, Francesco
    Neumann, Frank
    Gao, Guozhi
    Tefferi, Ayalew
    BLOOD, 2013, 122 (21)
  • [26] Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial
    Shimoda, Kazuya
    Komatsu, Norio
    Matsumura, Itaru
    Ikeda, Kazuhiko
    Hino, Masayuki
    Hidaka, Michihiro
    Maeda, Yoshinobu
    Kondo, Takeshi
    Fujisaki, Tomoaki
    Shoshi, Keita
    Azuma, Kyoichi
    Fukushima, Ryuichi
    Kawashima, Jun
    Kosugi, Hiroshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (03) : 314 - 324
  • [27] A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis
    Daver, Naval G.
    Kremyanskaya, Marina
    O'Connell, Casey
    Dao, Kim-Hien
    Oh, Stephen T.
    Gerds, Aaron T.
    Verstovsek, Srdan
    Erickson-Viitanen, Sue
    Zhou, Feng
    Assad, Albert
    Yacoub, Abdulraheem
    BLOOD, 2018, 132
  • [28] Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF)
    Verstovsek, S.
    Mesa, R. A.
    Gotlib, J. R.
    Levy, R. S.
    Gupta, V.
    DiPersio, J. F.
    Catalano, J.
    Deininger, M.
    Miller, C. B.
    Silver, R. T.
    Talpaz, M.
    Winton, E. F.
    Harvey, J. H.
    Vaddi, K.
    Erickson-Viitanen, S. K.
    Koumenis, I.
    Sun, W.
    Sandor, V.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naive Myelofibrosis Patients
    Mascarenhas, John
    Harrison, Claire
    Luptakova, Katarina
    Wang, Jing
    Colak, Gozde
    Shao, James
    Bobba, Suresh
    Trojer, Patrick
    Humphrey, Jeffrey
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S363 - S363
  • [30] Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
    Mead, Adam
    Mascarenhas, John
    Gerds, Aaron
    Luptakova, Katarina
    Christo, Jessica
    Wang, Jing
    Colak, Gozde
    Shao, James
    Bobba, Suresh
    Trojer, Patrick
    Humphrey, Jeffrey
    Verstovsek, Srdan
    Harrison, Claire
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 101 - 102
12345